Related by context. All words. (Click for frequent words.) 66 fidaxomicin Phase 65 Pivotal Phase 65 Initiate Phase 65 AZX# Phase 64 placebo controlled Phase 64 Initiated Phase 64 treatment naive genotype 63 HCV RESPOND 2 63 Pivotal Phase III 63 initiated Phase Ib 63 Randomized Phase 63 randomized controlled Phase 62 phase IIb clinical 62 omacetaxine mepesuccinate 62 multicenter Phase 62 Phase #b/#a clinical 62 retinal vein occlusion induced 62 Phase IIb clinical trials 62 dose cohort 62 ALN VSP Phase 62 Successfully Completes Phase 62 JZP 61 IIb clinical trial 61 oral ridaforolimus 61 SUCCEED trial 61 MKC# MT 61 Phase IIIb clinical 60 lintuzumab SGN 60 Phase IIb trials 60 HCV SPRINT 60 Commences Phase 60 APF# Phase 60 BRIM3 60 Allovectin 7 60 phase IIb study 60 antibody MAb 60 PRE SURGE 60 GOUT 60 Phase Ib IIa 60 GVAX R 60 Phase III HEAT 60 APPRAISE 60 PRECISE trial 60 including eniluracil ADH 60 Matrix Phase 2b 60 ENDEAVOR III 60 AIMM trial 60 PF # [002] 60 CRMD# 60 phase IIa clinical 59 MIVI III 59 Phase Ib II 59 LUX Lung 59 Phase 2a clinical trials 59 SinuNase TM 59 IMPACT DCM 59 Phase 2b Clinical Trial 59 Oxypurinol 59 opioid induced bowel dysfunction 59 Dacogen injection 59 FOLOTYN ® 59 multicenter Phase II 59 dose escalation clinical 59 treatment naïve genotype 59 interferon gamma 1b 59 forodesine 59 Completes Patient Enrollment 59 Aflibercept 59 telomerase inhibitor drug 59 ongoing Phase 1b 59 Androxal TM 59 satraplatin Phase 59 Phase IIB 59 Achieves Primary Endpoint 59 LymphoStat B TM 58 dose escalation Phase 58 sodium thiosulfate STS 58 Actimmune ® 58 phase IIb trial 58 TELINTRA R 58 E1 INT TM 58 CALGB # [002] 58 Corlux 58 Aloxi injection 58 Phase 2b kidney transplant 58 Tramiprosate ALZHEMED TM 58 Sulonex 58 BCIRG 58 Commence Phase 58 MEND CABG II 58 HCD# [002] 58 pivotal Phase 58 Initiates Phase 58 PLK1 SNALP 58 FORTIS M trial 58 ILUVIEN ® 58 Phase Ib study 58 markets Testim ® 58 RECORD1 58 Phase 1a clinical 58 Initiates Phase II 58 TASKi2 58 phase IIb 58 SPRYCEL ® 58 lorcaserin Phase 58 initiate Phase IIa 58 pralatrexate injection 58 trial evaluating Prochymal 58 elotuzumab 58 Solazed 58 TLK# 58 VICTOR E1 58 CIMZIA TM certolizumab pegol 57 Phase lll 57 Phase III randomized controlled 57 Phase 2b study 57 INS# [001] 57 refractory metastatic colorectal cancer 57 Viprinex TM 57 induced macular edema 57 CLL SLL 57 Phase Ib clinical 57 Phase IIA 57 dosing cohort 57 Phase IIb III 57 MIST II 57 HDL Selective Delipidation 57 PDX pralatrexate 57 Brentuximab Vedotin SGN 57 Cloretazine ® 57 Phase III Pivotal 57 novel histone deacetylase 57 Phase #b/#a trial 57 DSMB recommended 57 deforolimus 57 AzaSite Plus 57 phase IIa 57 fidaxomicin Phase 3 57 Nasdaq PGNX today 57 Phase 2b clinical trials 57 randomized Phase 2b 57 EOquin TM 57 oral methylnaltrexone 57 PFO migraine 57 ORENCIA ® 57 SinuNase ™ 57 evaluating tesamorelin 57 Aryplase 57 Amrubicin 57 metastatic sarcomas 57 ACCLAIM COPD 57 TG MV 57 Neo Bladder Augment 57 Fibrillex TM 57 LymphoStat B Phase 57 bicifadine 57 preclinical pharmacokinetic 57 bardoxolone 57 multicenter randomized Phase 57 Metastatic Melanoma 57 PEG IFN 57 placebo controlled Phase III 57 Phase III Clinical Trial 57 mg/m2 dose 57 MAA submission 57 Phase Ib Clinical Trial 57 phase IIb III 57 Phase #b/#a 57 XL# SAR# 57 Trial Evaluating 57 Phase 2a clinical 57 BrachySil TM 57 omecamtiv mecarbil 57 stated Michelle Berrey 57 MKC# 57 budesonide foam 57 EXPAREL TM 56 Phase IIb Clinical Trial 56 dextromethorphan quinidine 56 assessing T DM1 56 evaluating Actimmune 56 Omigard 56 Troxatyl 56 #mg dosing group 56 Sulonex TM 56 Diabetic Macular Edema 56 Ecallantide 56 Hedgehog pathway inhibitor 56 IMC #B 56 Raptiva R 56 UPLYSO 56 anti CTLA 56 CONSERV 56 cancer neuroendocrine tumor 56 Parathyroid Hormone 56 talactoferrin 56 GetGoal Phase III 56 registrational trial 56 Testosterone MDTS ® 56 Panzem R NCD 56 PSMA ADC 56 Civacir 56 THALOMID 56 initiated Phase 1b 56 candidates Dyloject TM 56 reslizumab 56 Arzerra ofatumumab 56 3 registrational trial 56 alemtuzumab Campath 56 Initiates Clinical 56 Initiates Phase 2b 56 Albuferon Phase 56 AEGR 56 histone deacetylase HDAC inhibitor 56 HoFH 56 sitaxsentan 56 octreotide implant 56 Nasdaq OPTR 56 ancrod 56 evaluable subjects 56 IMPACT IMmunotherapy 56 Phase IIb 56 subcutaneous methylnaltrexone 56 verteporfin 56 PRECISE Trial 56 AERx iDMS 56 rALLy 56 trastuzumab DM1 T DM1 56 CHAMPION PCI 56 candidate AQ4N 56 TEMSO 56 BR.# 56 Phase 2b randomized 56 ELACYT 56 OvaRex ® MAb 56 MGd 56 Dextofisopam 56 PEG PAL 56 Phase 1b clinical trials 56 metastatic renal cell 56 pivotal Phase III 56 Xibrom QD 56 catheter occlusion 56 Spiegelmer ® 56 Phase 2a preventative 56 Drug Eluting Stent System 56 Phase III ThermoDox 56 Second Pivotal Phase 56 confirmatory Phase III 56 multicenter Phase III 56 TASKi3 56 PANVAC VF 56 phase Ib clinical 56 OPT CHF 56 Omacetaxine 56 adecatumumab MT# 56 Inc. NASDAQ NLTX 56 multicenter randomized placebo controlled 56 BRIM2 55 Multiple Ascending Dose 55 phase III ACCLAIM 55 NASDAQ OMER 55 Amoxicillin PULSYS Phase III 55 oral deforolimus 55 Phase 1b 55 Inc. Nasdaq VVUS 55 Urocortin 2 55 GENASIS clinical 55 PRECiSE 55 PREOS R 55 Pivotal Phase II 55 Meets Primary Endpoint 55 Phase III psoriasis 55 Phase IIa trial 55 tramiprosate Alzhemed TM 55 vernakalant hydrochloride 55 BLA filing 55 rALLy clinical trial 55 Quinamed 55 nalbuphine ER 55 RELOVAIR ™ 55 Zerenex 55 Phase 2a trial 55 EFAPROXYN TM efaproxiral 55 Fx #A 55 OVATURE 55 STEALTH C 55 ORENCIA R 55 CLARITY study 55 QLT# 55 Phase IIb clinical 55 budesonide MMX 55 huC# DM4 55 PROVENGE ® 55 Central Retinal Vein 55 registrational 55 apoptosis inducer 55 PreCISe 55 Genasense ® oblimersen 55 huN# DM1 55 EDEMA3 55 ONCONASE R 55 imetelstat GRN#L 55 Phase III VISTA 55 midstage clinical 55 tolevamer 55 Randomized Phase II 55 ularitide 55 trial evaluating PRX# 55 phase 2a 55 dosing cohorts 55 Prosaptide 55 RezularTM 55 SinuNase 55 non nucleoside inhibitor 55 Hedgehog Pathway Inhibitor 55 fostamatinib 55 Phase 1b clinical 55 Prestara 55 Confirmatory Phase 55 Phase IIIb 55 dacetuzumab SGN 55 Virulizin R 55 Cloretazine R VNP#M 55 Xcytrin R 55 CINTREDEKIN BESUDOTOX 55 Bicifadine 55 Severe Sepsis 55 Phase IIb Trial 55 Phase III ALLEGRO 55 INCB# [001] 55 telomerase therapeutic 55 omiganan 55 multicenter placebo controlled 55 Phase 2b clinical 55 perifosine KRX 55 phase IIIb 55 T Pred 55 QNEXA ® 55 tosedostat 55 dexanabinol 55 inhaled AAT 55 systemic Phase 1b 55 Phase Ib clinical trials 55 AQ4N 55 Proellex TM 55 multicentre randomized double 55 evaluating bafetinib 55 EVIZON TM squalamine lactate 55 RE LY ® 55 eniluracil 55 IL# PE#QQR 55 BLA submission 55 maribavir 55 confirmatory Phase 3 55 MOZOBIL 55 IIa trial 55 ARISE Phase III 54 underwent resection 54 Hedgehog antagonist 54 intravenous methylnaltrexone 54 Camvia 54 EmbraceAC 54 polycythemia vera essential thrombocythemia 54 Itopride 54 Targretin capsules 54 BiovaxID Phase 54 randomized Phase IIb 54 Bezielle 54 ENDEAVOR II 54 phase III isavuconazole 54 Advaxis Phase 54 nucleotide analog 54 Actimmune R 54 vidofludimus 54 Testosterone MDTS R 54 POSIDUR TM 54 myeloid metaplasia 54 Pivotal Trial 54 Initiate Clinical Trial 54 Combination REOLYSIN R 54 Phase III clinical 54 Tocosol Paclitaxel 54 Personalized Immunotherapy 54 trastuzumab DM1 54 cisplatin vinorelbine 54 Glypromate 54 multicenter phase 54 Pivotal Clinical Trial 54 PREGNANT Study 54 compound INCB# 54 generation purine nucleoside 54 Phase 2b trial 54 Phase III ADT 54 PI3K/Akt pathway inhibitor 54 Milestone Payments 54 ARCOXIA 54 Phase IIa trials 54 MoxDuo IR 54 NSABP B 54 non splenectomized 54 controlled multicenter Phase 54 Veronate 54 Elagolix 54 recurrent malignant glioma 54 BrachySil ™ 54 Phase III randomized 54 initiate Phase 2b 54 GRNVAC1 54 MEND CABG 54 multicenter randomized controlled 54 CytoFabTM 54 biliary tract cancer 54 LymphoStat B belimumab 54 TELCYTA 54 Soliris TM eculizumab 54 BST CarGel R 54 APEX PD 54 EndoTAG TM -1 54 RESTORE CLI trial 54 albiglutide 54 Zenvia ™ 54 cetuximab Erbitux 54 R#/MEM # 54 MoxDuo TM IR 54 Efficacy Results 54 Dyloject TM 54 Novel Oral 54 pediatric acute lymphoblastic 54 relapsed refractory multiple myeloma 54 Harry Palmin President 54 ENRICH trial 54 lumiliximab 54 NDA Submission 54 Anturol TM 54 severe hypercholesterolemia 54 brivaracetam 54 alvimopan 54 oxymorphone ER 54 Stimuvax R 54 systemic ALCL 54 Benlysta belimumab 54 GATTEX TM 54 novel VDA molecule 54 Cleviprex TM clevidipine 54 RAPTIVA R 54 telaprevir dosing 54 Kamada AAT 54 MAGE A3 ASCI 54 Ocrelizumab 54 Phase III 54 Phase III Clinical Trials 54 Phase IIa clinical 54 Pivotal Study 54 ALSYMPCA 54 GVAX ® 54 REVIVE TA 54 PRIMO CABG 54 Gentamicin Surgical Implant 54 Xcellerated T Cells 54 ADVEXIN clinical 54 phase Ib 54 INSPIRE Trial Phase III 54 diabetic neuropathic pain 54 Dose Ranging Study 54 Initiate Phase II 54 UVIDEM 54 celgosivir 54 CCR5 mAb 54 acetonide FA 54 Xelox 54 Phase Ib 54 initiate Phase 1b 54 ofatumumab HuMax CD# 54 ENDEAVOR IV 54 evaluating TLN 54 Prednisone Against Refractory 54 rALLy trial 54 VITAL Trial 54 Phase 54 HYVISC R 54 incyclinide 54 Panzem ® 54 novel therapeutic antibodies 54 Diabetic Macular Edema DME 54 Velcade bortezomib 54 hypoxia activated prodrug 54 rindopepimut 53 Renal Cell Carcinoma RCC 53 Randomized Evaluation 53 SNT MC# 53 CRp 53 apricitabine ATC 53 hour bronchodilation 53 initiate Phase Ib 53 resectable pancreatic cancer 53 orally administered inhibitor 53 multicenter randomized double 53 PSN# [002] 53 SVR# 53 OHR/AVR# 53 Viramidine 53 investigational humanized monoclonal antibody 53 Thalomid ® 53 Exherin TM 53 Phase III multicenter 53 TMC# [002] 53 TKB# 53 IND submission 53 recurrent glioblastoma multiforme 53 Ketotransdel 53 Luveniq 53 Allovectin 7 R 53 L BLP# 53 AMD# [002] 53 masked placebo controlled 53 Phase III pivotal 53 TBC# 53 REG2 53 ANCHOR trial 53 Phase 2b Trial 53 investigational monoclonal antibody 53 dose escalation 53 NSABP 53 vinorelbine tartrate 53 mertansine 53 Tarsa oral calcitonin 53 evaluating satraplatin 53 AAG geldanamycin analog 53 ARRY # 53 docetaxel Taxotere R 53 P#X# antagonist 53 inhibitor RG# 53 generation DACH Platinum 53 treat opioid induced 53 treats paroxysmal nocturnal 53 Phenoptin 53 LUMINATE 53 glufosfamide 53 Pivotal Trials 53 ARDIS 53 Cloretazine R 53 ruxolitinib 53 anagrelide hydrochloride 53 QNEXA 53 VIVITROL ® 53 TKM ApoB 53 Zenvia Phase III 53 virus HCV protease inhibitor 53 ridaforolimus 53 Presents Positive Preclinical 53 Flutiform ™ 53 FavId 53 GLP toxicology studies 53 ACTEMRA TM 53 Raptiva ® 53 Ixempra 53 Canvaxin 53 evaluating tivozanib 53 ZYBRESTAT TM 53 intranasal formulation 53 GALNS 53 indiplon capsules 53 lexidronam injection 53 torezolid phosphate 53 Thrombin 53 Phase IIB clinical 53 lomitapide 53 metastatic hormone refractory 53 Archexin 53 candidate Liposomal Grb 53 Phase II 53 selective androgen receptor modulator 53 Saforis 53 Phase 1b dose escalation 53 Azedra TM 53 Qnexa TM 53 PDE inhibitor 53 GENASIS trial 53 RELIANT Trial 53 relapsed MM 53 Oral Calcitonin 53 #mg dose [002] 53 Dose escalation 53 Phase IIa Clinical Trial 53 LEP ETU 53 EVIZON ™ 53 Sorafenib HCC Assessment 53 Phase III Trial 53 occlusion PAO 53 Completes Enrollment 53 buccal spray 53 RIGScan CR 53 candidate WF# 53 sunitinib Sutent 53 CLIRS trial 53 aflibercept 53 AERx ® 53 candidate XP# 53 Patients Treated With 53 metastatic CRC 53 acyclovir Lauriad R 53 Phase #/#a 53 mGluR5 negative 53 CUSTOM III 53 Zenvia TM 53 acute mania 53 PHX# 53 EVIZON TM 53 NASDAQ CXSP announced 53 JAK1 53 evaluating mipomersen 53 HGS ETR2 53 diarrhea predominant irritable 53 PegIFN RBV 53 PEGylated Fab fragment 53 pharmacokinetic PK study 53 IMA# 53 TRANSFORMS 53 MT# MEDI 53 iii GTx 53 dose cohorts 53 INTERCEPT platelets 53 refractory gout 53 Clolar ® 53 Prostate AdenoCarcinoma Treatment 53 Phase #/#a trial 53 CIP TRAMADOL ER 53 punctal plug delivery 53 brentuximab vedotin SGN 53 MAXY alpha 53 oral Hsp# inhibitor 53 BEMA Granisetron 53 Dosa suffers 53 PROVENGE sipuleucel T 53 Ozarelix 53 Genasense ® 53 Pre RELAX AHF 53 NEVO RES 53 AeroLEF TM 53 EVEREST II 53 Tesetaxel 53 CTAP# Capsules 53 RSD# iv 53 Prodarsan R 53 personalized cellular immunotherapy 53 Inhalation Solution 53 pegloticase 53 refractory chronic lymphocytic 53 Lymphoseek ® 53 IIa trials 53 Onalta ™ 53 randomized Phase 53 Cimzia TM 53 RhuDex TM 52 PTK# 52 Alequel ™ 52 Shows Statistically Significant 52 volociximab 52 Phase 2a Clinical Trial 52 BEMA Buprenorphine 52 fosbretabulin 52 PRIMO CABG2 52 OLpur TM MD 52 subcutaneous formulation 52 BENLYSTA ® 52 de novo kidney transplant 52 STRIDE PD 52 Plicera 52 orally inhaled migraine 52 MYDICAR 52 Arimidex anastrozole 52 Diamyd ® 52 midstage trials 52 IV Busulfex 52 Phase 2a Trial 52 seliciclib CYC# 52 Factor VIIa 52 Ceflatonin R 52 pradefovir 52 baminercept 52 PNP inhibitor 52 TORISEL 52 PC DAC Exendin 52 Phase IIb kidney transplant 52 liposomal formulation 52 leukemia AML 52 cannabinor 52 histamine dihydrochloride 52 investigational compounds 52 investigational protease inhibitor 52 evaluating Xcytrin 52 ADVANCE PD 52 HDAC Inhibitor 52 PLAVIX ® 52 platinum refractory 52 prospective multicenter randomized 52 systemic anaplastic large 52 Alzhemed TM 52 R Interferon beta 52 TRO# 52 Phase III confirmatory 52 Pimavanserin 52 GVAX immunotherapy 52 Forodesine HCl 52 molecular imaging radiopharmaceutical 52 Nuvion 52 Ophena TM 52 oral prodrug 52 EMPHASIS HF trial 52 RhuDex ® 52 Vitaxin 52 Degarelix 52 VNP#M 52 Ereska 52 Phase 1a 52 pivotal bioequivalence 52 TAXUS Element Stent System 52 mesylate tablets 52 otelixizumab 52 LibiGel testosterone gel 52 ThermoDox R 52 recurrent GBM 52 Specifid 52 Panzem R 52 Randomised 52 SYMMETRY trial 52 Phase 1b Clinical Trial 52 romidepsin novel 52 Phase Ia 52 Retisert TM 52 Phase 2a Study 52 Virulizin 52 GLP1 agonist 52 DASISION 52 Phase IIb trial 52 EFAPROXYN 52 Phase 2a 52 stage IIIb IV 52 R sorafenib tablets 52 goserelin 52 thetreatment 52 Intravitreal 52 TRISENOX ® 52 Phase IIa clinical trials 52 initiate Phase IIb 52 TNFerade TM 52 Canvaxin TM 52 Serada 52 DAC HYP 52 PPAR gamma agonist 52 EXPAREL ™ 52 Zerenex ™ 52 anticancer compound 52 galiximab 52 ATL# [001] 52 Hormone Refractory Prostate Cancer 52 dependent kinase inhibitor 52 velafermin belinostat 52 alvespimycin 52 Zerenex Phase 52 RE SURGE 52 relapsed MCL 52 ATAC Arimidex Tamoxifen Alone 52 randomized multicenter 52 Wyeth Progenics 52 Aurexis 52 Phase III placebo controlled 52 PEGINTRON TM 52 transthyretin TTR mediated amyloidosis 52 PROMACTA 52 immunotherapeutic vaccine 52 neurogenic orthostatic hypotension 52 valopicitabine NM# 52 angiographic outcomes 52 PS# DARA 52 cutaneous T 52 Cloretazine 52 Clinical Trial Results 52 Vitrasert R 52 R bendamustine hydrochloride 52 Thorough QT 52 desvenlafaxine succinate 52 randomized multicenter Phase III 52 Æterna Zentaris 52 Vicriviroc 52 clinicaltrials 52 severe oral mucositis 52 Vascular Wrap TM 52 PEG SN# 52 enoximone capsules 52 PrevOnco ™ 52 immunosuppressive compound 52 oral FTY# 52 GRN# 52 SPIRIT FIRST 52 eculizumab 52 PROTECT AF 52 rhIGFBP 3 52 MADIT 52 relapsed AML 52 HGS# 52 rhIGF-I/rhIGFBP-3 52 Azedra 52 PentaStaph 52 NEBIDO 52 crizotinib PF # 52 Nasdaq MAPP 52 epoetin alpha 52 PRESEPT study 52 evaluating Vectibix 52 Phase 2b 52 REVIVE Diabetes 52 ANTEGREN 52 ENDEAVOR IV clinical 52 relapsed multiple myeloma 52 sNDA submission 52 BLOOM Behavioral modification 52 Traficet EN 52 Oral Fingolimod 52 Amgen Neulasta ® 52 clinical pharmacology studies 52 Entereg TM 52 topically administered 52 neurologic progression 52 Soliris eculizumab 52 JAK3 inhibitor 52 ITAX 52 VANTAS R 52 Annamycin 52 ACCLAIM trial 51 TRACON Pharmaceuticals Inc. 51 EURIDIS 51 Nasdaq NYMX 51 Efficacy Trial 51 inhaled treprostinil 51 GVAX 51 metastatic castration resistant 51 Study GL# 51 sodium glucose cotransporter 51 Eniluracil 51 tramiprosate ALZHEMED TM 51 PEGylated interferon beta 1a 51 Evoltra R 51 Maximum Tolerated Dose 51 metastatic castrate resistant 51 prospective randomized placebo 51 relapsing remitting MS RRMS 51 Genasense R oblimersen 51 recurrent metastatic 51 dual endothelin receptor antagonist 51 SEPET TM 51 FORTIS M 51 apaziquone 51 Tykerb lapatinib 51 mRCC 51 isavuconazole 51 zanolimumab 51 solanezumab 51 brain metastases originating 51 Neupogen ® 51 Alocrest 51 methylnaltrexone 51 TNFerade ™ 51 AVOREN 51 double blinded placebo 51 successfully commercialize Iluvien 51 ospemifene 51 ICA # 51 disease progression TTP 51 apricitabine 51 integrin inhibitor 51 Phase 2b monotherapy 51 Insegia 51 ABILIFY ® 51 AEG# 51 REMINYL ® 51 Telintra 51 ApoB SNALP 51 ZEVALIN ® 51 PrevOnco 51 AZX# 51 CATIE AD 51 midstage studies 51 AVADO 51 proprietary transdermal patch 51 SNS# T 51 Azedra ™ 51 SAR# [004] 51 NEO3 51 OvaRex R 51 aclidinium 51 Anturol ® 51 ROCKET AF 51 eculizumab therapy 51 AGGRASTAT R Injection tirofiban 51 DepoCyt 51 DCCR 51 RSD# oral 51 Study Evaluating 51 EDEMA4 51 ONTAK 51 EndoTAG 51 A1PI 51 Zybrestat 51 generation rotary VAD 51 drug pipeline TAFA# 51 Phase III TRIST 51 clazosentan 51 bavituximab monotherapy trial 51 pexelizumab 51 CEQ# 51 Diamyd R 51 PEARL SC 51 peginesatide 51 Luramist TM 51 label multicenter 51 Cinquil 51 Septin9 51 ILLUMINATE 51 valopicitabine 51 labial herpes 51 Tarceva TM 51 OvaRex 51 sunitinib malate 51 BiovaxID TM 51 product candidate Lpathomab 51 Feasibility Trial 51 Dacogen decitabine 51 Fibrin Pad 51 OLpur TM H2H 51 evaluating REVLIMID 51 ponatinib 51 Biopharmaceuticals AG 51 Xeloda ® 51 Aganocide 51 DR Cysteamine 51 placebo controlled randomized 51 multiple myeloma MM 51 ocrelizumab 51 ROTATEQ 51 2 methoxyestradiol 51 R#/MEM 51 leading oral taxane 51 teriflunomide 51 IND Investigational New 51 TELINTRA 51 Rhucin R 51 ara C 51 Daclizumab 51 Asentar 51 corticosteroid dexamethasone 51 methylnaltrexone bromide 51 relapsing multiple sclerosis 51 JAK inhibitor 51 interferon ribavirin 51 bevasiranib 51 PRT# 51 GEM OS2 51 PA# [002] 51 confirmatory clinical 51 metastatic CRPC 51 OAB overactive bladder 51 clinical trials SGN 51 dasatinib Sprycel ® 51 unblind 51 advanced carcinoid 51 dirucotide 51 RhuDex 51 XIENCE V demonstrated 51 Trofex 51 Ceflatonin ® 51 recurrent herpes labialis 51 TAXUS ATLAS 51 drug eluting coronary stent 51 DCVax R Prostate 51 Investigational Treatment 51 oral taxane 51 Cetrorelix 51 darapladib 51 Zemplar Capsules 51 BLP# Liposome Vaccine 51 ABSORB trial 51 refractory cutaneous T 51 delivery polymer matrix 51 Bayer HealthCare Onyx Pharmaceuticals 51 PRNewswire FirstCall Genta Incorporated 51 TOCOSOL Paclitaxel 51 Bioral Amphotericin B 51 MADIT II 51 Rebif ® 51 Tavocept 51 SABCS 51 PRTX 51 generation antisense inhibitor 51 EMPHASIS HF 51 bone marrow reticulin deposition 51 methionine aminopeptidase 51 miconazole MBT